Identification of POA as a Novel Phosphatase of Akt Kinase in a Genome-Wide Functional Genomic Screen

Xueyan Duan,Tao Shen,X. Gao,Jin Zhang,Xin-Hua Feng,Xia Lin
DOI: https://doi.org/10.1016/j.jss.2009.11.453
IF: 2.417
2010-01-01
Journal of Surgical Research
Abstract:The PI3 K/Akt signaling pathway controls a wide spectrum of key cellular functions, including cell proliferation and differentiation. The central player Akt is activated by lipid PIP3, which generated by PI3 K and inactivated by tumor suppressor PTEN. Excessive PI3 K/Akt activity or loss of PTEN is often associated with tumorigenesis. Subsequently, full activation of Akt requires its phosphorylation at T308 and S473 by PKD and mTOR, respectively. Recently, we identified a novel protein phosphatase POA as a negative regulator of Akt in a functional genomic screen. Since the PI3 K/Akt signaling is tightly regulated, we hypothesize that POA regulates cellular functions through dephosphorylating Akt. Hence, it is vitally important to investigate the underlying mechanisms and functions for how POA regulates Akt signaling. Objective: (1) To determine whether POA physically interacts with and dephosphorylates Akt, and (2) to investigate how the POA-mediated dephosphorylation terminates the functions of Akt. Methods: We undertook a genome-wide functional genomic screen to identify phosphatases that directly dephosphorylated Akt. Akt phosphorylation in response to insulin or other growth factors was analyzed in normal and tumor cells using immunological methods such as immunoprecipitation (IP), western blotting, immunofluorescence and fluorescence resonance energy transfer (FRET). Effects of POA overexpression and POA knockdown on the level of Akt dephosphorylation were determined by anti-phospho-Akt Western blotting. Real-time PCR and transcriptional analyses of Akt target genes were carried out to determine the functions of POA in regulating Akt responses. POA and its phosphatase-dead mutant were examined for their ability to dephosphorylate Akt, and to affect cell proliferation. Cell proliferation was measured by MTT assays and 3H-thymidine incorporation, and apoptosis detected by caspase cleavage. Muscle differentiation was analyzed in C2C12 myoblasts via myofiber staining. Results: In response to insulin or PDGF, Akt became phosphorylated at T308 and S473. A functional genomic screen identified a novel phosphatase termed POA as a potential Akt phosphatase. Increased expression of POA, but not its phosphatase-dead mutant, abolished growth factor-induced phosphorylation in multiple assays (e.g. IP-Western and FRET). We found that POA could directly interact with Akt in cells and in vitro, and this interaction occurred in the cytoplasm. Importantly, the ability of POA to dephosphorylate Akt was reflected by the functional consequence of POA overexpression or knockdown, which influenced cell proliferation, survival and myoblast differentiation. Conclusion: POA is a novel regulator of the critical PI3 K/Akt signaling pathway. It is conceivable that manipulation of POA activity may provide a platform of intervening the activity of Akt during cancer development.
What problem does this paper attempt to address?